Loading…

Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent

The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2006-08, Vol.320 (1), p.157-164
Main Authors: Malzert-Fréon, A., Vrignaud, S., Saulnier, P., Lisowski, V., Benoît, J.P., Rault, S.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles. From interfacial tension measurements and from the study of the rheological interfacial properties of the tripentone at the Labrafac ®–Solutol ® interface, the fraction of tripentone initially present in Labrafac ® would stay in the oily core of nanocapsules. Moreover, the interpenetration of some tripentone molecules within the surfactant units helps to the stabilization of the formulated nanoparticles. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC) and was found to be above 95%. In vitro release studies were carried out in blank nanoparticles containing phosphate buffer, pH 7.4, at 37 °C. The drug release kinetics was measured by HPLC. Antiproliferative activity studies on L1210 cells showed that the cytotoxic activity of tripentone was totally recovered after encapsulation of the antitubulin agent in lipid nanoparticles. This study shows that lipid nanocapsules could be a promising and effective carrier for tripentone delivery in the treatment of cancers.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2006.04.007